文献速递血液净化与透析肾移植

血液透析与肾移植患者骨源性和血管源性分子生物标志物的预后价值:系统综述与Meta分析

Prognostic value of bone- and vascular-derived molecular biomarkers in hemodialysis and renal transplant patients: a systematic review and meta-analysis.
PubMed 文献 · Nephrol Dial Transplant · 2017-01-01

该系统综述与Meta分析共纳入21项研究,评估血液透析和肾移植患者中FGF23、OPG等骨源性和血管源性分子生物标志物与死亡率的关联。在血液透析患者中,基线FGF23较低三分位与较高三分位相比,全因死亡和心血管死亡的合并HR分别为1.94(95%CI 1.47-2.56)和2.4(95%CI 1.64-3.51);OPG的预后价值仅限于心血管死亡。肾移植受者中FGF23和OPG与死亡率的关系仍需进一步研究。

要点

  • 血液透析患者基线FGF23较低三分位与较高三分位相比,全因死亡合并HR为1.94(95%CI 1.47-2.56)。
  • 血液透析患者基线FGF23较低三分位与较高三分位相比,心血管死亡合并HR为2.4(95%CI 1.64-3.51)。
  • 血液透析患者基线OPG较低三分位与较高三分位相比,心血管死亡合并HR为2.53(95%CI 1.29-4.94)。

核心结论

  • 在血液透析患者中,FGF23是全因死亡和心血管死亡的预测因素,而OPG的预测价值仅限于心血管死亡。
  • 肾移植受者中这些生物标志物的预后价值仍需进一步研究。

研究设计与样本

  • 系统综述与Meta分析,系统检索MEDLINE和Embase两个数据库。
  • 初检共识别1170项研究,最终21项符合纳入标准。
  • 纳入标准为报告生物标志物与死亡率关联的风险比(HR)或固定随访时间的效应量(OR)的研究。
  • 提取的HR转换为标准效应尺度后采用随机效应模型合并。

主要发现

  • 血液透析患者中,基线FGF23较低三分位与较高三分位相比,全因死亡合并HR为1.94(95%CI 1.47-2.56),心血管死亡合并HR为2.4(95%CI 1.64-3.51)。
  • 血液透析患者中,基线OPG较低三分位与较高三分位相比,全因死亡合并HR为1.8(95%CI 0.95-3.39),心血管死亡合并HR为2.53(95%CI 1.29-4.94)。
  • RANK配体、OPN、Klotho蛋白和BMP-7的风险估计不适宜合并,仅Klotho蛋白与死亡率显著相关。
  • 肾移植受者中,4项研究探讨了FGF23和OPG与死亡率的关系,均报告了显著关联。

局限性

  • RANK配体、OPN、Klotho蛋白和BMP-7的风险估计不适宜合并。
  • 肾移植受者中这些生物标志物的预后价值仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients undergoing hemodialysis and kidney graft recipients are high-risk populations for cardiovascular and all-cause mortality. Fibroblast growth factor 23 (FGF23), osteoprotegerin (OPG), RANK ligand, osteopontin (OPN), Klotho protein and bone morphogenetic protein-7 (BMP-7) are bone- and vascular-derived molecular biomarkers that have been shown to be associated with cardiovascular surrogate end points; however, currently available data on the prognostic value of these biomarkers is inconsistent. The aim of the present study was to conduct a systematic review and meta-analysis in order to summarize the available evidence on the association of molecular biomarkers with mortality in individuals undergoing hemodialysis and renal transplant patients. METHODS: Two databases (MEDLINE and Embase) were systematically searched. Studies were eligible if the association of biomarker and mortality was reported as time-to-event data [hazard Ratio (HR)] or as effect size with a fixed time of follow-up [odds Ratio (OR)]. Abstracted HRs were converted onto a standard scale of effect and combined using a random effects model. RESULTS: From a total of 1170 studies identified in initial searches, 21 met the inclusion criteria. In hemodialysis patients, comparing the lower third with the upper third of baseline FGF23 distribution, pooled HRs (95% confidence intervals) were 1.94 (1.47, 2.56) for all-cause mortality and 2.4 (1.64, 3.51) for cardiovascular mortality. For the same comparison of baseline OPG distribution, pooled HRs were 1.8 (0.95, 3.39) for all-cause mortality and 2.53 (1.29, 4.94) for cardiovascular mortality. Reported risk estimates of RANK ligand, OPN, Klotho protein and BMP-7 were not suitable for pooling; however, only Klotho protein was significantly related to mortality. For kidney graft recipients, four studies that investigated the relationship of FGF23 and OPG with mortality were identified, all of which reported a significant association. CONCLUSIONS: In hemodialysis patients, FGF23 is a predictor of all-cause and cardiovascular mortality, whereas the predictive value of OPG is restricted to cardiovascular mortality. Further studies are needed in order to gain insight into the prognostic value of these biomarkers in renal transplant recipients.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Pichler G, Haller MC, Kainz A, et al. Prognostic value of bone- and vascular-derived molecular biomarkers in hemodialysis and renal transplant patients: a systematic review and meta-analysis. Nephrol Dial Transplant. 2017. PMID: 28025385. doi:10.1093/ndt/gfw387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。